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23 Sweat testing in a tertiary clinic − reasons, results and
methodology
L. Mense1, S. Bauer1, J. Hammermann1. 1University Hospital Carl Gustav Carus,
Department of Pediatrics, Dresden, Germany
Objectives: Sweat testing following pilocarpin iontophoresis is the preferred
method to check for cystic ﬁbrosis. Correct measurement and interpretation of
results are essential components of cystic ﬁbrosis testing.
Methods: All sweat tests performed in the years 2005 to 2010 in our cystic
ﬁbrosis centre were analyzed retrospectively. Pilocarpin iontophoresis was in ac-
cordance to established international guidelines. All samples were analyzed using
chloridometry (Chloridmeter, Kreienbaum, Germany) and conductivity measure-
ment (SweatCheck, WesCor Inc., USA). Results were interpreted as negative,
indeterminate or positive according to international guidelines (chloridometry) or
manufacturer’s recommendation (conductivity measurement).
Results: 1246 sweat tests were performed on 1077 patients. 68 patients were
18 years or older. Median age at testing was 1.58 years (min. 14 days, max.
77 years). Comparison of conductivity measurement and chloridometry reveals
a constantly higher NaCl equivalent in conductivity measurement (mean value
of difference 24.1±10.7mmol/l). In 91.4% the assessment of test results reveals
consistent diagnoses. 0.9% of patients would not have received a second test if only
conductivity measurement had been used although chloridometry revealed positive
or indeterminate results.
Discussion: Sweat testing remains a particularly paediatric topic. The gold stan-
dard is chloridometry. This study underlines the inappropriate comparability of
conductivity measurement and chloridometry with consequently higher values in
conductivity measurement. Special reference values allow a consistent interpretation
in many cases but not in all.
24 Direct potentiometric measurement for chloride ion using
Spotchem Arkray analyser adapted to sweat samples
T. Nguyen-Khoa1, R. Myled2, J.-P. Borgard2, M. Rota2. 1CHU Necker-Enfants
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Background: Sweat test measuring the chloride ion (Cl−) concentration in sweat
is a tool for the cystic ﬁbrosis (CF) diagnosis. We evaluated analytical criteria of
a direct potentiometric device and compared chloride results to those obtained by
coulometry from a same sweat collection.
Methods: Sweat tests were performed after pilocarpine iontophoresis (Pilogels™
and 3700 Webster Sweat Check Inducer™, Wescor, Elitech). Sweat was collected
using Macroduct™ system (Wescor, Elitech). For 139 patient sweat samples col-
lected in two laboratory hospitals, chloride ion concentration was determined by
coulometry (Chloridometer 926S Sherwood, Dutscher) and by direct potentiometry
using a Spotchem™ EL Se-1520 analyser (Arkray, Elitech) for which urine mode
was selected and calibration factor modiﬁed for sweat measurements.
Results: Linearity range was demonstrated in the range 10 to 140mmol/L Cl−.
Within-run and between-run variation coefﬁcients were 2.0% for 24mmol/L Cl−,
1.8% for 51mmol/L Cl− and 1.2% for 101mmol/L Cl−. The correlation (Passing-
Bablock) between chloridometer analyser and Spotchem™ was y = 1.026 + 1.8
(r = 0.996) with a bias (Bland and Altman, p< 0.001). After correction by the
regression factors, only 6 (4.6%) results remained without ±5mmol/L Cl−.
Conclusions: Our work indicates that Spotchem™ analyser presents analytical
criteria satisfying international guidelines for CF diagnosis. All its process was
simple, rapid and independent of operator variability. Its availability should lead to
improved accuracy of sweat test results in laboratories where less reliable methods
are used.
25 Body plethysmography for measuring nasal airway resistance:
a diagnostic tool?
M.C. Berkhout1, G.W.M. van der Meijden1, E. Rijntjes2, H.G.M. Heijerman1.
1Haga Teaching Hospital, Pulmonary Diseases, The Hague, Netherlands; 2Haga
Teaching Hospital, Otorhinolaryngology, The Hague, Netherlands
Subjective sensation of nasal patency often shows large discrepancy with objective
ﬁndings. Therefore is it desirable to ﬁnd a technique to measure nasal patency.
Body plethysmography is a validated technique to measure the airway resistance.
Based on this theory, body plethysmography can be used for measuring nasal airway
resistance (NAR).
Objective: Investigation of the reliability of body plethysmography for measuring
nasal airway resistance.
Methods: Twenty healthy subjects (15 females and 5 males; aged 24−61 years)
were included in this pilotstudy. The NOSE questionnaire was used to measure
subjective nasal resistance.
For measuring the NAR, the subject was placed in a body box with a CPAP mask
covering mouth and nose. Three measurements followed; breathing through the
mouth, breathing through the nose and a second measurement through the nose
after administration of the decongestant xylometazoline HCl 0.1%. This whole
procedure was repeated under the same conditions after 4−39 days.
Conclusions: The intraclass correlation coefﬁcient (ICC) of body plethysmography
for measuring NAR is 0.485. This ICC indicates a low reliability of the test for
measuring NAR. After administration of xylometazoline the ICC was 0.382.
In conclusion, the reliability of body plethysmography (body box) for measuring
the nasal airway resistance is poor and therefore it is not useful as diagnostic tool.
26 NPD measurements in subjects with borderline sweat test
B. Tu¨mmler1, C. Acevedo1, M. Lenz1, A. Schulz1. 1Medizinische Hochschule
Hannover, Clinic for Pediatric Pneumology, Allergology and Neonatology,
Hannover, Germany
Thanks to the recently developed Standard Operating Procedures of the CFFT
TDN and the ECFS DNWG transepithelial nasal potential measurements (NPD)
can now be performed with unprecedently high reproducibility and signal-to-noise
ratios in subjects suspected to suffer from cystic ﬁbrosis (CF). Of 30 subjects
who had been referred to our clinic during the last year because of symptoms of
sinopulmonary and/or gastrointestinal disease and sweat chloride concentration in
the range of 20−80mmol/L, CF was excluded in the majority of subjects because of
NPD tracings in the normal range. PS-CF was diagnosed in ﬁve subjects and was
conﬁrmed by the detection of two CFTR mutations including those with variable
penetrance such as L206W and D1152H. Four individuals, however, could not be
assigned to the established categories of PI CF, PS CF, CFTR-RD or non-CF. These
subjects exhibited a normal basal potential and amiloride response and a residual
chloride conductance upon exposure to chloride-free solution and isoprotenerol in
the grey zone between CF and non-CF. One subject was carrying F508del and a yet
undescribed sequence variant in the acceptor splice site of intron 11 in trans. In the
other three subjects no sequence variation had been identiﬁed in the CFTR coding
region. We would like to conclude that the improved NPD technique can detect
subjects with mild CFTR dysfunction who cannot be classiﬁed by the currently
recommended global diagnostic algorithm for CF and CFTR-RD.
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